Table 2 Estimated 10-year OS rates.
Nilotinib 300 mg twice daily | Nilotinib 400 mg twice daily | Imatinib 400 mg once daily | |
|---|---|---|---|
OS | |||
All patients, n | 282 | 281 | 283 |
OS events, n | 32 | 24 | 29 |
Estimated rate of OS, % (95% CI) | |||
At 5 years | 93.7 (90.8–96.6) | 96.3 (94.0–98.5) | 91.8 (88.5–95.1) |
At 10 years | 87.6 (83.5–91.7) | 90.3 (86.5–94.1) | 88.3 (84.2–92.4) |
HR vs imatinib (95% CI) | 1.07 (0.64–1.76) | 0.79 (0.46–1.36) | NA |
P vs imatinib | 0.80 | 0.40 | NA |
OS on study by age at baseline | |||
Patients <60 years, na | 223 | 228 | 224 |
OS events in patients <60 years, n | 15 | 11 | 21 |
Estimated rate of OS at 10 years, % (95% CI) | 92.7 (89.1–96.3) | 94.5 (91.3–97.7) | 89.7 (85.5–93.9) |
Patients ≥60 years, na | 59 | 53 | 59 |
OS events in patients ≥60 years, n | 17 | 13 | 8 |
Estimated rate of OS at 10 years, % (95% CI) | 67.0 (53.7–80.4) | 69.4 (54.6–84.2) | 83.4 (72.8–94.1) |
OS on study by Sokal risk score at baseline | |||
Patients in low Sokal risk group, na | 103 | 103 | 104 |
OS events, n | 5 | 5 | 1 |
Estimated rate of OS at 10 years, % (95% CI) | 94.7 (90.3–99.2) | 94.1 (89.1–99.1) | 98.8 (96.4–100) |
Patients in intermediate Sokal risk group, na | 101 | 100 | 101 |
OS events, n | 12 | 9 | 14 |
Estimated rate of OS at 10 years, % (95% CI) | 88.0 (81.3–94.7) | 89.6 (83.2–96.1) | 84.3 (76.6–92.1) |
Patients in high Sokal risk group, na | 78 | 78 | 78 |
OS events, n | 15 | 10 | 14 |
Estimated rate of OS at 10 years, % (95% CI) | 76.5 (65.9–87.1) | 85.9 (77.3–94.6) | 78.9 (68.8–88.9) |
